Genentech Inc. is turning again to Seattle Genetics Inc.'s antibody-drug conjugate platform, as the Bothell, Wash.-based biotech racks up additional licensing fees ahead of anticipated Phase III data and marketing submissions for lead internal lymphoma drug SGN-35. (BioWorld Today) Read More
